NASDAQ:KLRA Kailera Therapeutics Q3 2026 Earnings Results & Report $12.80 +0.22 (+1.75%) As of 04:00 PM Eastern Kailera Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.74 versus the -$1.55 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call7:00 AM ET Kailera Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$1.55Beat/MissBeat by +$0.81One Year Ago EPSN/AKailera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kailera Therapeutics Q3 2026 Earnings FAQ Did Kailera Therapeutics beat earnings estimates for Q3 2026? Kailera Therapeutics (NASDAQ:KLRA) reported earnings of -$0.74 per share for Q3 2026, beating the consensus estimate of -$1.55. The report was announced on Wednesday, November 4, 2026. Kailera Therapeutics Earnings HeadlinesKailera Reports Third Quarter 2026 Financial Results and Provides Business Updates3 hours ago | globenewswire.comKailera Therapeutics to Participate in November Investor ConferencesNovember 3 at 7:15 AM | globenewswire.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 4 at 1:00 AM | Decentralized Masters (Ad)Kailera Therapeutics (KLRA) Stock Forecast & Price TargetOctober 11, 2026 | investing.comKailera Therapeutics Inc Presents New Phase 1 Data For Ribupatide Injection At EASD 2026 Annual MeetingOctober 1, 2026 | marketscreener.comMKailera Therapeutics Announces Phase 1 Ribupatide Data Showing Flexible Injection Sites and Additional Hengrui Pharma Clinical Presentations at EASD 2026October 1, 2026 | quiverquant.comQSee More Kailera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email. Email Address About Kailera TherapeuticsKailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases. The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones. Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited. The company does not currently have an established portfolio of marketed products described in the available information.View Kailera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
